A randomised phase III trial of high dose palliative radiotherapy (HDPRT) versus concurrent chemotherapy and HDPRT (C-HDPRT) in patients with good performance status, locally advanced/small volume metastatic NSCLC not suitable for radical chemo-radiotherapy.
The purpose of this study is to investigate whether adding chemotherapy to a short (less than six weeks) course of radiotherapy results in a greater improvement in symptoms and overall wellbeing (quality of life) compared with using a short course of radiotherapy alone in patients with Non-Small Cell Lung Cancer (NSCLC) who cannot be treated with surgery or a long (six weeks or longer) course of radiotherapy and chemotherapy.
Primary Sponsor
Trans-Tasman Radiation Oncology Group (TROG)
Final Accrual
76
Trial Chairperson
Associate Professor Margot Lehman, Princess Alexandra Hospital, QLD
Clinical Trial Registration
Related Post
18 October, 2022
NINJA Radiation Therapy Trial participant tells his journey to treatment
The journey to becoming the 200th participant for the
6 September, 2022
The gift that kept on giving
The NewyWay Coffee Collaboration Newcastle marketing agency, The Marketing
